$PEN
Penumbra Inc

2016 Q2 Form 10-Q Financial Statement

#000132173216000022 Filed on August 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2015 Q2
Revenue $65.11M $42.31M
YoY Change 53.87% 34.41%
Cost Of Revenue $23.64M $14.94M
YoY Change 58.25% 38.55%
Gross Profit $41.47M $27.38M
YoY Change 51.49% 32.25%
Gross Profit Margin 63.7% 64.7%
Selling, General & Admin $35.88M $26.40M
YoY Change 35.91% 63.95%
% of Gross Profit 86.51% 96.42%
Research & Development $6.264M $4.792M
YoY Change 30.72% 16.88%
% of Gross Profit 15.1% 17.51%
Depreciation & Amortization $600.0K $400.0K
YoY Change 50.0% 135.29%
% of Gross Profit 1.45% 1.46%
Operating Expenses $42.14M $31.19M
YoY Change 35.12% 55.16%
Operating Profit -$670.0K -$3.813M
YoY Change -82.43% -735.5%
Interest Expense $559.0K $177.0K
YoY Change 215.82%
% of Operating Profit
Other Income/Expense, Net -$272.0K -$542.0K
YoY Change -49.82% 442.0%
Pretax Income -$383.0K -$4.178M
YoY Change -90.83% -894.3%
Income Tax -$3.396M -$1.507M
% Of Pretax Income
Net Earnings $3.013M -$2.671M
YoY Change -212.8% -783.12%
Net Earnings / Revenue 4.63% -6.31%
Basic Earnings Per Share $0.10 -$0.11
Diluted Earnings Per Share $0.09 -$0.11
COMMON SHARES
Basic Shares Outstanding 30.21M shares 5.096M shares
Diluted Shares Outstanding 33.31M shares 5.096M shares

Balance Sheet

Concept 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $139.9M $36.80M
YoY Change 280.16%
Cash & Equivalents $13.91M $36.76M
Short-Term Investments $125.9M $0.00
Other Short-Term Assets $2.488M $11.70M
YoY Change -78.74%
Inventory $68.41M $44.20M
Prepaid Expenses $4.753M
Receivables $34.58M $23.60M
Other Receivables $3.300M $1.900M
Total Short-Term Assets $260.2M $118.2M
YoY Change 120.15%
LONG-TERM ASSETS
Property, Plant & Equipment $11.86M $8.000M
YoY Change 48.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $441.0K $2.900M
YoY Change -84.79%
Total Long-Term Assets $23.73M $10.90M
YoY Change 117.68%
TOTAL ASSETS
Total Short-Term Assets $260.2M $118.2M
Total Long-Term Assets $23.73M $10.90M
Total Assets $283.9M $129.1M
YoY Change 119.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.070M $3.700M
YoY Change 10.0%
Accrued Expenses $28.12M $21.70M
YoY Change 29.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.19M $26.90M
YoY Change 19.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.199M $1.800M
YoY Change 133.28%
Total Long-Term Liabilities $4.199M $1.800M
YoY Change 133.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.19M $26.90M
Total Long-Term Liabilities $4.199M $1.800M
Total Liabilities $36.39M $28.70M
YoY Change 26.79%
SHAREHOLDERS EQUITY
Retained Earnings -$12.17M
YoY Change
Common Stock $30.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $247.6M $100.4M
YoY Change
Total Liabilities & Shareholders Equity $283.9M $129.1M
YoY Change 119.94%

Cashflow Statement

Concept 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income $3.013M -$2.671M
YoY Change -212.8% -783.12%
Depreciation, Depletion And Amortization $600.0K $400.0K
YoY Change 50.0% 135.29%
Cash From Operating Activities -$6.110M -$5.670M
YoY Change 7.76% -367.45%
INVESTING ACTIVITIES
Capital Expenditures -$2.580M -$1.770M
YoY Change 45.76% 555.56%
Acquisitions
YoY Change
Other Investing Activities $1.280M $39.25M
YoY Change -96.74% -130933.33%
Cash From Investing Activities -$1.300M $37.48M
YoY Change -103.47% -12593.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.940M -3.300M
YoY Change -249.7% -106.54%
NET CHANGE
Cash From Operating Activities -6.110M -5.670M
Cash From Investing Activities -1.300M 37.48M
Cash From Financing Activities 4.940M -3.300M
Net Change In Cash -2.470M 28.51M
YoY Change -108.66% -45.47%
FREE CASH FLOW
Cash From Operating Activities -$6.110M -$5.670M
Capital Expenditures -$2.580M -$1.770M
Free Cash Flow -$3.530M -$3.900M
YoY Change -9.49% -263.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-445000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34000 USD
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
3.641
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0 USD
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001321732
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31054604 shares
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
Penumbra Inc
CY2015Q4 pen Allowancefor Sales Returns Current
AllowanceforSalesReturnsCurrent
3247000 USD
CY2016Q2 pen Allowancefor Sales Returns Current
AllowanceforSalesReturnsCurrent
3040000 USD
CY2015Q4 pen Clinical Trial Accruals Current
ClinicalTrialAccrualsCurrent
1330000 USD
CY2016Q2 pen Clinical Trial Accruals Current
ClinicalTrialAccrualsCurrent
1769000 USD
pen Numberof Business Activities
NumberofBusinessActivities
1 activity
pen Productsand Services Numberof Markets
ProductsandServicesNumberofMarkets
2 market
pen Provisionfor Sales Returns
ProvisionforSalesReturns
223000 USD
pen Provisionfor Sales Returns
ProvisionforSalesReturns
-208000 USD
CY2015 pen Standardand Extended Product Warranty Accrual Increase Decreasefor Changesin Estimatefor Newand Preexisting Warranties
StandardandExtendedProductWarrantyAccrualIncreaseDecreaseforChangesinEstimateforNewandPreexistingWarranties
752000 USD
pen Standardand Extended Product Warranty Accrual Increase Decreasefor Changesin Estimatefor Newand Preexisting Warranties
StandardandExtendedProductWarrantyAccrualIncreaseDecreaseforChangesinEstimateforNewandPreexistingWarranties
345000 USD
pen Stock Issuance Costs Incurred During Noncashor Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction
620000 USD
pen Stock Issuance Costs Incurred During Noncashor Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction
0 USD
pen Writeoffof Note Receivable
WriteoffofNoteReceivable
85000 USD
pen Writeoffof Note Receivable
WriteoffofNoteReceivable
0 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2567000 USD
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4070000 USD
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
29444000 USD
CY2016Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34577000 USD
CY2015Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
308000 USD
CY2016Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
139000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25581000 USD
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28119000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5071000 USD
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6201000 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2115000 USD
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2579000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
252087000 USD
CY2016Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
266650000 USD
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3261000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3616000 USD
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3522000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6537000 USD
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
602000 USD
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
589000 USD
CY2016Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
661000 USD
CY2015 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0 USD
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0 USD
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3241163 shares
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
0 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
4373000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3241163 shares
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0 USD
CY2016Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
20665000 USD
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
62983000 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36764000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19547000 USD
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15210 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38935 shares
CY2015Q4 us-gaap Assets
Assets
263848000 USD
CY2016Q2 us-gaap Assets
Assets
283979000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
244361000 USD
CY2016Q2 us-gaap Assets Current
AssetsCurrent
260252000 USD
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000 USD
CY2016Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
326000 USD
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
269000 USD
CY2016Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000 USD
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
129512000 USD
CY2016Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
125629000 USD
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
269000 USD
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
6000 USD
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
97802000 USD
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
12032000 USD
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
129257000 USD
CY2016Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
125949000 USD
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
66274000 USD
CY2016Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
105284000 USD
us-gaap Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments
AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments
-541000 USD
us-gaap Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments
AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments
2000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
483000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
560000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3290000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13914000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
33474000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5633000 USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
30000 USD
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
30000 USD
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2151000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-538000 USD
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1608000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
501000 USD
CY2015Q2 us-gaap Cost Of Revenue
CostOfRevenue
14936000 USD
us-gaap Cost Of Revenue
CostOfRevenue
27160000 USD
CY2016Q2 us-gaap Cost Of Revenue
CostOfRevenue
23636000 USD
us-gaap Cost Of Revenue
CostOfRevenue
41650000 USD
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
526000 USD
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
411000 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
0 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-207000 USD
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
4373000 USD
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-239000 USD
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
27600000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1185000 USD
CY2015Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.361
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
10143000 USD
CY2016Q2 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
11422000 USD
CY2015Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
745000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
700000 USD
CY2016Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
600000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1146000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1100000 USD
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2016Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
1.483
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.445
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13653000 USD
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15401000 USD
CY2015 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
300000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
600000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-12000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-59000 USD
CY2015Q2 us-gaap Gross Profit
GrossProfit
27375000 USD
us-gaap Gross Profit
GrossProfit
54103000 USD
CY2016Q2 us-gaap Gross Profit
GrossProfit
41470000 USD
us-gaap Gross Profit
GrossProfit
81375000 USD
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4178000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
64000 USD
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-383000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1738000 USD
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1507000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
233000 USD
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-568000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
773000 USD
CY2015Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
606000 USD
CY2016Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
3273000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
548000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1330000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4940000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5058000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4709000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3435000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
11321000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
12035000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2759000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5508000 USD
CY2015Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
177000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
385000 USD
CY2016Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
559000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1069000 USD
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
44839000 USD
CY2016Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
54671000 USD
CY2015Q4 us-gaap Inventory Net
InventoryNet
56761000 USD
CY2016Q2 us-gaap Inventory Net
InventoryNet
68406000 USD
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
9176000 USD
CY2016Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
10560000 USD
CY2015Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2746000 USD
CY2016Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3175000 USD
us-gaap Inventory Write Down
InventoryWriteDown
304000 USD
us-gaap Inventory Write Down
InventoryWriteDown
824000 USD
CY2015Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
800000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1400000 USD
CY2016Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1300000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2400000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
31326000 USD
CY2016Q2 us-gaap Liabilities
Liabilities
36388000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
263848000 USD
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
283979000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28148000 USD
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
32189000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2974000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7803000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45018000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
304000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8331000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12555000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-2671000 USD
us-gaap Net Income Loss
NetIncomeLoss
-169000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
185000 USD
us-gaap Net Income Loss
NetIncomeLoss
965000 USD
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-553000 USD
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
185000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
965000 USD
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-553000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-34000 USD
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
185000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
965000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
31188000 USD
us-gaap Operating Expenses
OperatingExpenses
53926000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
42140000 USD
us-gaap Operating Expenses
OperatingExpenses
80210000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3813000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
177000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-670000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1165000 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5273000 USD
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6127000 USD
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1304000 USD
CY2016Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2488000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
393000 USD
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
441000 USD
CY2015Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
193000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
220000 USD
CY2016Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
88000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
369000 USD
CY2015Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
327000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-589000 USD
CY2016Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1881000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-833000 USD
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3178000 USD
CY2016Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4199000 USD
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-542000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-498000 USD
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-272000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-496000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
964000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2525000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1846000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
4069000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
27467000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3073000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3695000 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9352000 USD
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
17406000 USD
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4706000 USD
CY2016Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4753000 USD
CY2015Q4 us-gaap Prepaid Taxes
PrepaidTaxes
2736000 USD
CY2016Q2 us-gaap Prepaid Taxes
PrepaidTaxes
6892000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
0 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
2504000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
52160000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
28962000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7983000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6264000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11265000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17475000 USD
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16510000 USD
CY2015Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
531000 USD
CY2016Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
497000 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3755345 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3489807 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.13
CY2015Q2 us-gaap Sales Revenue Net
SalesRevenueNet
42311000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
81263000 USD
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
65106000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
515000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1493000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3783000 USD
CY2014Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
314000 USD
CY2015Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
713000 USD
CY2016Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
735000 USD
CY2015Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
713000 USD
CY2016Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
735000 USD
CY2015 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
353000 USD
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
323000 USD
us-gaap Product Warranty Expense
ProductWarrantyExpense
176000 USD
us-gaap Product Warranty Expense
ProductWarrantyExpense
23000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14022000 USD
CY2016Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18065000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8951000 USD
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11864000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-101000 USD
CY2015 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-13000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
72000 USD
CY2015Q4 us-gaap Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
5000 USD
CY2016Q2 us-gaap Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
0 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4792000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
123025000 USD
CY2015Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26396000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
45943000 USD
CY2016Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35876000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
68945000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3616000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
6537000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
11983 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.56
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.80
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
0 USD
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5096151 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
19.13
CY2016Q2 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
148354 shares
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
148354 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
253555 shares
CY2016Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3800000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3800000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
232522000 USD
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
247591000 USD
CY2015Q2 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-2118000 USD
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-135000 USD
CY2016Q2 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 USD
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 USD
CY2015Q2 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
-2118000 USD
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
-135000 USD
CY2016Q2 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
0 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5000375 shares
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32693684 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32542253 shares
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5096151 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5000375 shares
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30210322 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30100162 shares
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business </font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Penumbra, Inc. (the &#8220;Company&#8221;) is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. The Company has a broad portfolio of products that addresses challenging medical conditions and significant clinical needs across </font><font style="font-family:Times New Roman;font-size:10pt;">two</font><font style="font-family:Times New Roman;font-size:10pt;"> major markets, neuro and peripheral vascular. The conditions that the Company&#8217;s products address include, among others, ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.</font></div></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and equity accounts; disclosure of contingent assets and liabilities at the date of the financial statements; and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to marketable investments, provisions for doubtful accounts, sales return reserve, warranty reserves, valuation of inventories, useful lives of property and equipment, income taxes, and contingencies, among others. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other data. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001321732-16-000022-index-headers.html Edgar Link pending
0001321732-16-000022-index.html Edgar Link pending
0001321732-16-000022.txt Edgar Link pending
0001321732-16-000022-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pen-063016x10q.htm Edgar Link pending
pen-063016xexhibit311.htm Edgar Link pending
pen-063016xexhibit312.htm Edgar Link pending
pen-063016xexhibit321.htm Edgar Link pending
pen-20160630.xml Edgar Link completed
pen-20160630.xsd Edgar Link pending
pen-20160630_cal.xml Edgar Link unprocessable
pen-20160630_def.xml Edgar Link unprocessable
pen-20160630_lab.xml Edgar Link unprocessable
pen-20160630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending